Patients with high-risk prostate cancer treated with curative intent are at an increased risk of
biochemical recurrence, metastatic progression and cancer-related death compared with …

The Y Box binding protein 1 (YB-1) is a member of the highly conserved Cold Shock Domain
protein family with multifunctional properties both in the cytoplasm and inside the nucleus …

The new-generation hormonal agent enzalutamide has been approved for the treatment of
metastatic castration-resistant prostate cancer (CRPC), in both post-and predocetaxel …

Endocrine therapies for prostate cancer inhibit the androgen receptor (AR) transcription
factor. In most cases, AR activity resumes during therapy and drives progression to …

PURPOSE The androgen receptor (AR) is expressed (+) in a subset of salivary gland
cancers (SGCs). This phase II trial evaluated the efficacy of the antiandrogen enzalutamide …

The androgen receptor (AR) is widely expressed in breast cancer, and evidence suggests
dependence on AR signaling for growth and survival. AR antagonists such as enzalutamide …

Intravenously administered radiolabeled peptides targeting somatostatin receptors are used
for the treatment of unresectable gastroenteropancreatic neuroendocrine tumors (GEP …

Purpose: ErbB2 signaling appears to be increased and may enhance androgen receptor
(AR) activity in a subset of patients with castration-resistant prostate cancer (CRPC), but …

Background/Aims: The human epidermal growth factor receptors tyrosine kinase inhibitor
lapatinib has been shown to trigger suicidal death or apoptosis of tumor cells and is thus …

Abstract Y-box-binding protein 1 (YB-1) is a DNA/RNA binding protein increasingly
implicated in the regulation of cancer cell biology. Normally located in the cytoplasm …